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Chronic inflammation is a major characteristic feature of Parkinson’s disease (PD).
Studies in PD patients show evidence of augmented levels of potent pro-inflammatory
molecules e.g., TNF-α, iNOS, IL-1β whereas in experimental Parkinsonism it has been
consistently demonstrated that dopaminergic neurons are particularly vulnerable to
activated glia releasing these toxic factors. Recent genetic studies point to the role of
immune system in the etiology of PD, thus in combination with environmental factors,
both peripheral and CNS-mediated immune responses could play important roles in
onset and progression of PD. Whereas microglia, astrocytes and infiltrating T cells
are known to mediate chronic inflammation, the roles of other immune-competent
cells are less well understood. Inflammation is a tightly controlled process. One major
effector system of regulation is HPA axis. Glucocorticoids (GCs) released from adrenal
glands upon stimulation of HPA axis, in response to either cell injury or presence of
pathogen, activate their receptor, GR. GR regulates inflammation both through direct
transcriptional action on target genes and by indirectly inhibiting transcriptional activities
of transcriptional factors such as NF-κB, AP-1 or interferon regulatory factors. In PD
patients, the HPA axis is unbalanced and the cortisol levels are significantly increased,
implying a deregulation of GR function in immune cells. In experimental Parkinsonism, the
activation of microglial GR has a crucial effect in diminishing microglial cell activation and
reducing dopaminergic degeneration. Moreover, GCs are also known to regulate human
brain vasculature as well as blood brain barrier (BBB) permeability, any dysfunction
in their actions may influence infiltration of cytotoxic molecules resulting in increased
vulnerability of dopamine neurons in PD. Overall, deregulation of glucocorticoid receptor
actions is likely important in dopamine neuron degeneration through establishment of
chronic inflammation.
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Introduction
Parkinson’s disease (PD) is a common age-related neurodegenerative disorder characterized
by cardinal motor symptoms that include bradykinesia with resting tremor, rigidity
and gait disturbance. These motor symptoms become evident when already 70--80% of
nigrostriatal terminals have degenerated. At present, therapeutic treatments, for example,
levodopa, mostly address motor symptoms. However, a wide spectrum of non-motor clinical
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features such as REM (Rapid eye movement) sleep disturbances,
autonomic dysfunction, depression, anxiety, cognitive
impairment or falling are associated with PD, and are moreover
debilitating and unresponsive to dopamine-related treatments.
Thus, PD is a complex systemic disorder with non-motor
symptoms often preceding motor symptoms and worsening
with disease progression (Berg et al., 2014; Goldman and
Postuma, 2014). PD has an age-adjusted incidence of 13.5--13.9
per 100.000 person-years, and a prevalence of 315 per 100,000
individuals (the second most common worldwide). As PD affects
predominantly older people, its prevalence increases with age
from 428 at 60--69 years to 1,903 per 100.000 in 80 years old
people (Abdullah et al., 2014; Pringsheim et al., 2014).
The major neuropathological hallmarks of PD are progressive
degeneration of dopaminergic neurons in the Substantia Nigra
pars compacta (SNpc); presence of proteinaceous inclusions
called Lewy bodies (LBs) and chronic inflammation. However,
the initial causes and underlying mechanisms pertaining to
these neuropathological features in the majority of patients,
classified as sporadic PD, remain unknown. Recent studies
indicate that combined genetic, environmental factors and aging
confer risk for developing sporadic PD rather than genetic
or environmental factor individually. Approximately 5--10%
of PD patients present the familial form of the disease with
either autosomal dominant or recessive mode of inheritance.
Epidemiological analysis confirm that up to 40% of PD patients
with age at onset of less than 30 years and 17% of those with
age at onset of less than 50 years will probably present the
familial form of the disease. At least 18 loci as well as 12 genes
with Mendelian inheritance and highly penetrant mutations
causing rare monogenic forms have been identified. The genetic
discovery of point mutations, duplication or triplication of SNCA
(synuclein) gene coding for α-synuclein protein (reviewed in
Goedert et al., 2013) with demonstration by Spillantini et al.
(1997) that α-synuclein is a major component of LBs, led Braak
et al. (2003) to staging PD according to appearance of α-
synuclein containing LBs and Lewy neuritis with disease severity.
Accordingly to Braak’s hypothesis PD progresses in neuronally-
connected ascending manner to dorsal motor nucleus of the
glossopharyngeal and vagus nerves likely from gut and/or
olfactory mucosa (stage 1 and 2), then from lower brain stem
to midbrain including nigral regions (stage 3 and 4) and lastly
to the neocortical regions (stage 5 and 6). However, it has been
suggested that LB pathology alone is not sufficient and that
associated neuronal loss leads to Parkinsonism (Buchman et al.,
2012).
In last few years, large genetic and genome-wide association
(GWA) studies together with meta-analyses have led to
significant and rapid advances in the genetic basis of sporadic
PD, with realization both for its wide implication and complexity
(Lill et al., 2012; Clarimón and Kulisevsky, 2013). There is
great expectation for further insights with advent of new DNA
sequencing technologies (exome and whole-genome sequencing)
and the NeuroX genotyping platform (Nalls et al., 2015). These
studies have identified at least 20 susceptibility loci as risk for
sporadic PD (Nalls et al., 2014). As yet, the true significance of
many of these loci is still unknown. Of interest, susceptibility
related to SNCA and LRRK2 (Leucine rich repeat kinase 2) loci
consistently observed are also genes that have been identified
in the monogenic, autosomal dominant familial PD patients.
Occurrence of somatic mosaicism has been also hypothesized in
the etiology of some cases of PD (Kim and Jeon, 2014). Cases
of somatic mosaicism in many central nervous system (CNS)
disorders have been reported, for example, somatic mutation
in the presenilin-1 gene associated with Alzheimer’s disease
(Beck et al., 2004), in SPG4/SPAST (spastic paraplegia4/spastin)
causing spastic paraplegia (Depienne et al., 2007) or MECP2
(methyl CpG binding protein) resulting in Rett syndrome (Topçu
et al., 2002). Thus far, no cases of PD with somatic mosaicism are
known, as well, in this regard results of study on SNCA somatic
mutations by Proukakis et al. (2014) were negative.
Summing up: (a) although at present there is a rapid
progress and evolution in technology to unravel genetic basis
of PD, most PD risk is not understood; (b) the pathogenicity
arising from several of identified gene mutations remains to
be determined; (c) highly penetrant gene mutations (as DJ-1,
LRRK2, Parkin, PINK1 (PTEN-induced putative kinase 1), and
SNCA) cause rare monogenic forms of the disease; (d) somatic
mosaicism could shed light on the heterogeneity of PD; and
(e) additive mechanisms is suggested in risk for PD, increasing
with the number of risk alleles carried by a single subject e.g.,
in HLA (human leucocyte antigen) region (Hill-Burns et al.,
2011).
There is strong epidemiological evidence to show that aging
is a single most important risk factor for PD, with increase
in incidence between fifth to eight decades. Modifications
that occur in specific brain regions during aging, such
as increased oxidative and nitrative stress, changes in glial
functions, dysfunction of proteasomes and lysosomes and altered
α-synuclein protein are also manifestations of PD (Collier
et al., 2011; Kieburtz and Wunderle, 2013). Environmental
toxins identified as risk for PD are herbicides (e.g., paraquat
or rotenone), heavy metals such as manganese and lead,
nanoparticles as air pollutants, head trauma or well water. Thus,
for example, it was shown that people exposed to pesticides
and harboring Cytochrome P450 2D6 (CYP2D6) genotype with
poor metabolic capacity for xenobiotics are at increased risk
for developing PD (Elbaz et al., 2004). Epidemiologic link
also exists between rotenone and PD. Rotenone is a powerful
inhibitor of mitochondrial complex 1 and interestingly complex
I deficiency is found in PD. The role of viral infections as risk
factor has been evoked ever since the famous and controversial
von Economo’s encephalitis lethargica pandemic suspected
to be caused by H1N1 (Hemagglutinin1 neuraminidase1)
influenza virus where patients exhibited Parkinsonism symptoms
(Ravenholt and Foege, 1982). Recently, animals infected with
highly pathogenic H5N1 virus showed clear motor deficits
as well human cases with encephalitis have been reported
(Jang et al., 2009). Epigenetic modifiers could be potential
mediators of environmental factors (Portela and Esteller,
2010). Aberrant epigenetic modifications include changes in
gene functions or gene expression but without changing
the DNA sequence: non-coding RNA-mediated changes of
gene expression, DNA methylation or post-transcriptional
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modifications and acetylation of histones (Nalls et al., 2014). For
instance, the methylation of the Tumor Necrosis Factor alpha
(TNF-α) promoter is significantly decreased in the SNpc of PD
patients compared with controls or with the methylation in the
cortex (Pieper et al., 2008) suggesting increased susceptibility
of dopamine neurons to TNF-α mediated inflammation (Barcia
et al., 2005, 2011).
Thus, aging together with genetic susceptibility and
cumulative environmental factors such as air pollutants,
pesticides, infections or exposure to heavy metals likely have a
role in the development of idiopathic PD.
Immune System and the Etiology of Parkinson’s
Disease
All of the above environmental factors together with multiple
cellular changes occurring during aging can impact immune
functions. There is now a growing realization, particularly from
genetic studies, that immune system is most likely involved in
the etiology as well as early phases of PD, thus the inflammatory
component of the disease may simply not be a consequence of
neuronal dysfunction and neurodegeneration. In GWA studies,
a number of susceptibility loci that have been identified as
strong risk factors, are related to both innate and adaptive
immune functions, for example, HLA-DQB1, LRRK2, GPNMB
(glycoprotein NMB), or BST-1 (bone marrow stromal cell
antigen) (Liu et al., 2011; Pihlstrøm et al., 2013). In this regard,
LRRK2, Parkin, PLA2G6 (phospholipase A2, group VI), DJ-1
and SNCA genes mutated in both familial and idiopathic PD are
also known to function in microglia and astrocytes (Russo et al.,
2014). Interestingly, several studies have identified risk of PD
with polymorphisms present in the promoter regions of IL-1β
and TNF-α genes that augment the expression of these genes and
whose protein products have potent pro-inflammatory activity
(Wahner et al., 2007). Moreover, polymorphisms reported
in other pro-inflammatory genes e.g., CD14, HLA-DBQ1,
HLA-DRA, HLA-DRB1, HLA-DRB5 can also increase the risk
for PD (Ahmed et al., 2012). In the analysis of potential
markers of motor and cognitive progression, SNPrs 6482992 of
clarin3 (CLRN3) was described as the best predictor of cognitive
deterioration (Chung et al., 2012) whereas SNPrs 10958605 as
involved in neuroinflammatory pathways (Cappellano et al.,
2013). The implication of early involvement of immune system is
also reinforced by epidemiological studies showing a prolonged
use of NSAIDs (Nonsteroidal anti-inflammatory) particularly
ibruprofen subsequently lowers the risk of PD (Rees et al.,
2011).
Neuroinflammation in PD
As a progressive neurodegenerative disorder, PD is a
multifactorial complex disease most likely evolving because
of the genetic and environmental risk factors, as well as cellular
alterations and aging. Inflammatory component in PD not
only encompasses deregulation of inflammatory pathways
resulting from genetic vulnerability but also immune alterations
associated with aging and with primary activation of glia in
the face of neuronal injury. Aging affects the functions of
immune system, resulting in so-called ‘‘immune senescence’’.
Specifically, advancing age has been associated with chronic
mild inflammation in the SNpc, thereby rendering dopaminergic
neurons vulnerable to degeneration (Kanaan et al., 2010).
Increasing evidence points to the role of active peripheral
inflammation in PD that can contribute to the initiation and/or
the progression of the disease by, for example, exacerbating and
synergizing with the discordant central inflammatory response
to drive dopaminergic neurodegeneration. Combination of
aging, heritable risk factors and exposure to environmental
agents has been suggested as potential host-pathogen specific
pathophysiologic elements that can cause deregulation of both
innate and adaptive immune system responses (Kanaan et al.,
2008; Chao et al., 2014). Thus, in both sporadic and familial PD,
immune activation occurring at multiple levels would play an
important role in PD pathology.
Evidence of an on-going neuroinflammation in affected
brain regions in PD stems from analyses of pro-inflammatory
cytokines (Interferon gamma, IFN-γ; TNF-α; Interleukin-6,
IL-6; or Interleukin-1β, IL-1β) showing their accumulation
in both cerebrospinal fluid and post-mortem brain (Mogi
et al., 1994; Dobbs et al., 1999; Reale et al., 2009a,b).
Recently, it has been demonstrated that the serum levels of
IL-6 and the chemokine ligand 5 (CCL5) also known as
Regulated on Activation, Normal T cell Expressed and Secreted
(RANTES) were significantly increased in PD patients, and
importantly, RANTES levels correlated with the severity and
duration of the disease (Tang et al., 2014). Furthermore, the
augmentation of iNOS (Inducible nitric oxide synthase) observed
in SN and striatum of PD (Hunot et al., 1996) suggests
that the toxicity originating both from cytokines/chemokines
and inflammation-derived oxidative stress could contribute to
dopaminergic neuronal degeneration and progression of the
disease (Orr et al., 2005; Wilms et al., 2007). Numerous
studies in experimental PD models indicate that dopamine
neurons are particularly vulnerable to both oxidative stress and
inflammatory attack (McGeer and McGeer, 2008; Pott Godoy
et al., 2008). Interestingly, in this regard, Lipopolysaccharide
(LPS)-activated microglia in the vicinity of dopamine neurons
in SN induce degeneration of these neurons whilst sparing
GABAergic and serotonergic neurons, suggesting a selective
dopamine neuron vulnerability to inflammation (Liu and Bing,
2011).
Inflammation and immune-related responses may be viewed
not only as determinant factors in disease progression but
also as pathogenic processes in the onset of both familial and
sporadic PD (Halliday and Stevens, 2011; Chao et al., 2014;
Dzamko et al., 2014). On this point, presence of activated
microglia, visualized by PET (positron emission tomography)
analysis using radioligand 11C-PK-11195, was recently reported
in the SN and putamen of PD patients diagnosed within a
year from clinical onset (Iannaccone et al., 2013). This, together
with study of Ouchi et al. (Ouchi et al., 2005) suggests a
microglial-mediated inflammatory process in early stage of
PD. Several lines of evidence also point to relevant actions
of different PD-linked gene mutations e.g., SNCA or LRRK2
in stimulating inflammatory responses through activation of
microglia and astrocytes thereby participating directly in chronic
Frontiers in Neuroanatomy | www.frontiersin.org 3 April 2015 | Volume 9 | Article 32
Herrero et al. Inflammation, Parkinson and glucocorticoids
PD progression (Gillardon et al., 2012; Moehle et al., 2012;
Harms et al., 2013). Both central and peripheral inflammation
occurs in the prodromal stage of PD, which thus sustains
disease progression (Dzamko et al., 2014; Su and Federoff,
2014). Overall, accumulation of pathological α-synuclein in
PD brain leads to neurodegeneration with T-cell infiltration,
microglial activation and increased production of inflammatory
cytokines and chemokines (Harms et al., 2013). The detection
of T lymphocytes and activated microglia in the SN of
Parkinsonian patients is striking because systemic immune cells
have to penetrate several barriers in order to reach the brain
parenchyma.
The CNS was considered as an immunologically privileged
site because of the lack of lymphatic vessels, the absence
of classical major histocompatibility complex (MHC) positive
antigen presenting cells, and the presence of barriers as
the tanycytic barrier around the circumventricular organs or
the neurovascular unit of the BBB. The latter is composed
of endothelial cells, pericytes and astrocytes and associated
strong, tight junctions prevent the entry of immune cells
into the brain parenchyma. BBB is a metabolic and physical
barrier that separates the CNS from the peripheral circulation,
actively allowing the transports of nutrients to the brain but
limiting passive diffusion of blood-borne solutes. However,
in aging and in PD, a BBB disruption has been described
with loss of the barrier permeability leading to secondary
leukocyte migration within the brain parenchyma, reactive
gliosis and damage to neurons (Stolp and Dziegielewska,
2009; Cabezas et al., 2014). BBB dysfunction in PD favors
an invasion of immune cells (and/or peripheral mediators
and factors as toxins or elements of adaptive immunity)
into the brain parenchyma that provokes a progressive and
self-perpetuating degenerative process (Monahan et al., 2008).
Additionally, it has been demonstrated that PD patients
have increased permeability of the intestinal epithelial barrier
(Forsyth et al., 2011) as well as chronic enteric/colonic
inflammation (Devos et al., 2013). As proposed by Braak et al.
(2003), an environmental pathogen can cross the monolayer
of polarized epithelial cells (the intestinal epithelial barrier)
(Sharkey and Savidge, 2014) and enter into the terminal
axons of the submucosal plexus spreading to the medulla
oblongata via the vagal preganglionic innervation of the gut
(Hawkes et al., 2009). Moreover, brain injuries or systemic
infections can induce systemic inflammatory responses that
easily communicate with brain. Both Alzheimer’s disease and
PD have been associated with both the HLA region (Ahmed
et al., 2012; Wissemann et al., 2013), and with the production of
autoantibodies (Maetzler et al., 2014) suggesting putative genetic
susceptibility to inflammation that could initiate the neuronal
dysfunction.
Microglia are the resident innate immune cells in the
brain. Being only 5--15% of the total cells of the brain,
microglia functions include tissue repair and cellular
homeostasis after neuronal injury. Activated microglia produce
neurotoxic molecules, for example, pro-inflammatory cytokines,
chemokines, complement proteins or nitric oxide. Additionally,
activated microglia acquire phagocytic properties and develop
neuro-immune interactions involving the expression of surface
molecules as CD200/CD200R, CD47/CD172a, CX3C chemokine
ligand 1 and its receptor (CX3CL1/CX3CR) and the complement
regulatory proteins, complement components C1q and C3 in
order to eliminate cellular debris and damaged neurons by
gliapses (Barcia et al., 2012). However, microglial responses
can have neuroprotective as well as harmful consequences
mainly if there is a continuous exposure to a pro-inflammatory
environment with a persistent release of inflammatory mediators
(Bardou et al., 2014) as activated microglia can still persist even
years after the toxic insults (Barcia et al., 2004; Jackson-Lewis
and Smeyne, 2005; Block et al., 2007). In fact, if as a defense
mechanism of the organism, an inflammatory response starts and
continues without control, a chronic persistent inflammation
environment in the brain can result in tissue destruction and
progressive neurodegeneration.
Glucocorticoids, Inflammation and Parkinson’s
Disease
Inflammation is normally a tightly regulated process that acts
to prevent pathogen invasion as well as cellular injury, whilst
at the same time enabling tissue repair. Several endogenous
mechanisms act to regulate the immune cell functions, which are
involved in triggering an inflammatory process. Among them,
the steroid hormone, glucocorticoid, is a known major regulator
of immune system and inflammation. Glucocorticoids (GCs) are
one of the most potent and effective anti-inflammatory agents in
clinical use ever since the isolation of cortisone and its clinical
application in the early 1950s by the Nobel Prize winners Hench,
Kendall and Reichstein (Hench et al., 1950; Reichstein, 1951).
GCs (cortisol in humans and corticosterone in rodents) are
endogenous steroid hormones synthesized in adrenal glands and
secreted into systemic circulation. The GC secretion occurs in
ultradian pulsatile manner (Hellman et al., 1970; Veldhuis et al.,
1989) and over-riding this pattern is acute GC rise in response to
a stressor (psychogenic or physical e.g., tissue injury or pathogen
invasion) whereby increased levels of GCs exert important
adaptive actions in multiple tissues to restore homeostasis
(Young et al., 2004; McEwen, 2007). Both ultradian/circadian
and stress-evoked GC secretion is tightly controlled by various
negative feedback mechanisms affecting each component of HPA
axis, notably synthesis and release of corticotropin-releasing
hormone (CRH) from the paraventricular nucleus (PVN) of the
hypothalamus and adrenocorticotropic hormone (ACTH) from
anterior pituitary. Any change in negative feedback loops will
affect HPA axis, resulting in altered ultradian/circadian rhythm
of GC release often with abnormally high basal GC levels, which
in turn could lead to GC resistance.
Measurement of plasma cortisol in idiopathic PD patients
has consistently shown significantly elevated levels compared
to age-matched control subjects, and as well correlating with
impulsive behaviors (Bellomo et al., 1991; Stypula et al., 1996;
Hartmann et al., 1997; Charlett et al., 1998; Djamshidian et al.,
2011; Ros-Bernal et al., 2011). The high cortisol levels seem
unrelated to L-DOPA treatment or disease duration (Müller
et al., 2007). Elevated cortisol levels are observed in many other
neurodegenerative diseases including Alzheimer disease (Huang
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et al., 2009). In PD, however, the normally quiescent nocturnal
cortisol secretory pattern is particularly affected (Hartmann
et al., 1997) raising the question as to whether the circadian
control of HPA axis by suprachiasmatic nucleus is altered. The
underlying causes of HPA deregulation and whether or how it
impacts PD pathology is presently not well understood. However,
presence of LBs in both adrenal glands and hypothalamus
in PD has been reported (Wakabayashi and Takahashi, 1997;
Braak et al., 2006), which may imply a role of α-synuclein
pathology in HPA axis deregulation. In addition to neuronal
networks regulating HPA axis through feed back loops, cytokines
liberated by peripheral immune cells can also stimulate HPA
axis in several ways. Potent inflammatory cytokines (TNF-α,
Il-1β and Il-6) can induce release of GCs by directly stimulating
CRH synthesizing neurons of PVN or indirectly by stimulating
production of prostaglandin E2 synthesis in perivascular cells
(Ericsson et al., 1994; Kang et al., 2006; Serrats et al., 2010). In
addition, IL-6 was shown to directly act on anterior pituitary
cells as well as in adrenal glands, via its receptor, to stimulate
the synthesis of ACTH and GC respectively (Zarkovi c´ et al.,
2008). Thus, deregulated immune responses with elevated levels
of pro-inflammatory cytokins may lead to chronic activation of
HPA axis.
Once secreted, GCs act on diverse physiological processes
ranging from metabolism, immune responses to cognition and
behavior. Their therapeutic potential, however, has limitations
as chronic use with sustained high levels of GCs can result
in serious side effects such as diabetes, obesity, dyslipidemia,
hypertension, osteoporosis or behavioral anomalies. GCs clearly
exert anti-inflammatory actions especially in an inflammatory
setting, however, a number of recent studies indicate that
they also exert pro-inflammatory responses, which are cell-
type dependent. Thus, in response to acute stress resulting in
increased GC levels, high levels of pro-inflammatory mediators
such as IL-1β were found (Dhabhar, 2002; O’Connor et al., 2003;
Sorrells et al., 2007). In a microarray study by Galon et al. (2002)
on human mononuclear cells, dexamethasone treatment was
found to induce the expression of several innate-immune related
genes in addition to down-regulation of pro-inflammatory genes.
It is believed that this opposing action of GCs ‘‘prepares’’ the
immune system to respond rapidly to harmful stimulus and
subsequently GCs act to down-regulate the immune response to
restore homeostasis.
Glucocorticoid Regulation of Inflammation
through GR
In brain, GC signaling is mediated by almost ubiquitously
expressed GRs (GRs) as well as mineralocorticoid receptors
(MR) that have restricted expression in neurons. However, it
should be noted that MR is also expressed in glia (Sierra et al.,
2008). GR, a prototype member of nuclear receptor superfamily
(designated as NR3C1 in nomenclature of nuclear receptor
family) is a ligand-activated transcription factor, it can also
exert non-genomic actions (Groeneweg et al., 2011). GR is a
modular protein with an N-terminal transactivation domain,
a C-terminal ligand binding domain (LBD) and a central Zinc
fingers-containing DNA-binding domain (DBD) that recognizes
a specific DNA sequence. The LBD is the high affinity binding
site for cortisol and other ligands. In humans, two major isoforms
of GR, hGRα and hGRβ arising from alternative splicing have
been described (Zhou and Cidlowski, 2005) and they differ
in their C-terminal ligand-binding domain such that hGRβ
cannot bind to endogenous or synthetic GCs. Experimental
evidence indicates that hGRβ is expressed at low levels and it
antagonizes the transcriptional activity of hGRα thus acting as
dominant negative inhibitor of hGRα. However, recent genome-
wide microarray studies indicate that hGRβ also regulates gene
transcription (Kino et al., 2009). Interestingly, reduction in
hGRα:hGRβ ratio has been associated with behavioral and
mood disorders such as depression and schizophrenia (Perlman
et al., 2004; Matsubara et al., 2006). In addition, alternative
translational initiation sites generating 8 different GR proteins
both in mouse and humans have been described (Oakley and
Cidlowski, 2013).
Recent evidence shows that pulsatile pattern of GC secretion
is crucial to proper GR transcriptional activity, thus loss of GC
oscillatory pattern can result in continuous transcription with
abnormal protein accumulation or GR targeting inappropriate
genes leading to undesirable outcomes. GR is normally inert
in the cytoplasm, in association with complex of proteins
including heat-shock chaperones (HSP90, HSP70, HSP40,
HSP23) and immunophilins such as FKBP51 (FK506 binding
protein51), FKBP52, CP44 and PP5 (Grad and Picard, 2007).
GC binding to this complex results in conformational change
in GR exposing a nuclear localization signal resulting in
importin-mediated translocation through the nuclear pore to the
nucleoplasm.
In the nucleus, GR regulates transcription of its target genes
in multiple, complex ways as well in highly cell- and context-
specific manner. The transcriptional activity of GR has been
especially studied with respect to its actions on metabolism and
regulation of immune responses in the periphery. Multitude of
studies indicates that GCs through GR influence each stage of
inflammatory response i.e., from initiation, effector to resolution
phases of an inflammatory reaction. Inflammatory response is
triggered by specific receptors in immune cells and in this regard
toll-like receptors (TLRs) activation and intracellular signaling
cascade is thus far best characterized (Kawai and Akira, 2010)
resulting in activation of transcriptional factors such as Nuclear
factor kappa B (NF-κB), Activator Protein 1 (AP-1) or interferon
response factors (IRFs). Each TLR family member (from
1--13 in mouse; all expressed in microglia) recognizes specific
molecular signature present in either pathogens (PAMPs-
Pathogen Associated Molecular Patterns) or molecules released
by injured cells called DAMPs (Damage-associated Molecular
Patterns). GR is reported to regulate key components of TLR
signaling e.g., transforming growth factor beta-activated kinase 1
(TAK1; Bhattacharyya et al., 2010).
The GR regulation of inflammation is a result of both its
transcriptional stimulatory and repressive activity. Classically,
GR stimulates transcription of genes that act to inhibit
inflammation and conversely it inhibits transcription of
pro-inflammatory genes. GR stimulates transcription as
homodimer binding to specific cognate DNA sequence,
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GAGAACAnnnTGTTCT, called Glucocorticoid Responsive
Elements (GREs) present in the promoter regions of its target
genes. This transcriptional activity of GR requires the presence
of chromatin modifiers (e.g., Nuclear receptor coactivator
NCoA1), basal transcriptional machinery and co-factors (CREB
binding protein CBP, p300) (Rosenfeld and Glass, 2001). This
mode of transcriptional activity has been notably described
for genes coding for proteins of metabolic pathways such
as glucose-6-phosphotase, fatty acid synthase or tyrosine
aminotransferase as well as anti-inflammatory genes e.g.,
(Nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor (IκB-α), MAPK phosphatase (MPK-1),
IL-4, IL-10 or annexin-1 (De Bosscher et al., 2003). GR can
also bind to negative GREs (nGREs) to repress transcription,
thus among the genes identified containing nGREs are CRH
as well as ACTH receptor in adrenal glands (Dostert and
Heinzel, 2004; Surjit et al., 2011). Importantly, with regards to
inflammation, GR can also inhibit transcription by tethering
(i.e., through protein-protein interactions) or modulating the
activity of other transcriptional factors, for example NF-κB,
AP1 or IRF (Chinenov et al., 2013). This action mediated by
GR monomers has been particularly studied in peripheral
immune cells involving inhibition of expression of powerful
pro-inflammatory genes as well as resolution of inflammation.
The cross talk between AP1, NF-κB and GR is well documented
(De Bosscher et al., 2003). As it has pertinence in the effects
of GR observed in microglia it will be briefly reiterated
here.
AP1 is comprised of heterodimers of c-Fos (C-Fos, FosB,
Fra1 and 2), Jun (c-N, B-Jun, D-Jun) as well as ATF
(Activating transcription factor) families of transcription factors,
which controls expression of many cytokines. AP1 activity
is stimulated by MAPK cascade resulting in activation of
c-Jun-N terminal kinase (JNK), which phosphorylates c-Jun. GR
regulates AP1 activity by associating with Jun-Fos complex at
AP1 DNA elements in promoter regions of genes, inducing a
conformational change in the complex that is not functional
(Diamond et al., 1990). Additionally, GR also stimulates
transcription of MAPK-phosphatase 1 (MKP-1) by binding to
GRE elements present in its promoter region (as mentioned
above) resulting in MKP-1 termination of JNK phosphorylation
activity on c-Jun.
NF-κB signaling in positive immune regulation has been
thoroughly characterized especially in the periphery (Karin and
Greten, 2005). NF-κB comprises of RelA (p65), RelB, c-Rel,
NF-κB1 (p50/p105 subunits) and NF-κB2 (p50/p100) proteins
and the transcriptionally active dimers identified are: p65/p50
(classic NF-κB), p65/p65, p65/c-Rel, RelB/p50, RelB/p52 and,
of note, Rel domains of these proteins bind to DNA. The
p65/p50 NF-κB protein is normally sequestered in the cytoplasm
by IκB family of proteins. NF-κB translocates to nucleus
following phosphorylation of IκB by IKK kinases followed
by rapid degradation of IκB. Importantly, phosphorylation
of the p65 subunit is important for NF-κB activation. This
involves phosphorylation of Serine 27Kuro6 of p65 by protein
kinase A (PKA) catalytic subunit in complex with NF-κB
and IκB as well as by nuclear localized MAPK-activated
mitogen- and stress-activated protein kinase 1 (MSK1) in
the nucleus. Interestingly GR was shown to decrease the
nuclear pool of MSK1 thus down regulating NF-κB activity
(Beck et al., 2008). With regards to its interaction with
NF-κB, it was shown that upon GR activation by GC, GR
is acetylated. In the nucleus, GR is deacetylated by histone
deacetylase (HDAC2) (Ito et al., 2006) before it can physically
bind to p65 subunit of NF-κB, functioning as transcriptional
antagonist. Another manner by which GR can terminate NF-κB
activation is by directly stimulating transcription of IκB-α as
mentioned above.
Innate Immune Regulation by GRs in Microglia
during Dopamine Neurodegeneration
In the CNS the role of endogenous GCs in regulating expression
of pro-inflammatory cytokines such as IL-1β, TNF-α or IL-6
was shown originally following peripheral administration of
LPS in adrenalectomized mice (Goujon et al., 1996). The
finding that HPA axis is reactive to CNS inflammation triggered
by an intrastriatal LPS injection was revealed through prior
challenge with systemic LPS that resulted in rise in systemic
corticosterone levels with concomitant and significant reductions
in proinflammatory TNF-α, Monocyte chemoattractant protein
MCP-1, IκBα transcripts in lesioned striatal/cortical region
(Nadeau and Rivest, 2002). Interestingly in this paradigm, LPS
does not trigger neuronal degeneration. However, neuronal
death was observed by prior treatment with GR antagonist
RU486 suggesting that GCs acting through GR prevent neuronal
degeneration (Nadeau and Rivest, 2003). Recently, the role
played by microglial GR in regulating neuronal survival in
this intrastriatal model of LPS was shown conclusively in mice
with selective inactivation of GR in microglia/macrophages,
GRLysMCre mice (Carrillo-de Sauvage et al., 2013). Inflammation
triggered by low dose of LPS (1--2 µg) injection has negligible
effect on striatal or cortical neurons (Carrillo-de Sauvage et al.,
2013), however the same dose of LPS injection in substantia
nigra causes specific loss of dopamine neurons (Castaño et al.,
2002) indicating a selective vulnerability of dopamine neurons
to microglial inflammatory response mediated by LPS-activated
TLR4. However, the fact that endogenous GCs activating GRs in
microglia are neuroprotective during LPS-induced inflammation
in cortex/striatum but not in midbrain substantia nigra implies
that their actions in microglia during TLR4 activation may be
region-specific. In this regard, recently the concept of microglial
heterogeneity with respect to their functional capabilities, for
example LPS/TLR4 signaling, has been evoked (Noh et al.,
2014).
Nigral dopamine neurodegeneration triggered by MPTP
is significantly reduced by pharmacological treatments with
GC agonists e.g., corticosterone that artificially increase
GCs above endogenous levels, conversely adrenalectomy
augments dopamine neuronal loss (Kurkowska-Jastrzebska
et al., 2004; Sugama et al., 2009; Ros-Bernal et al., 2011)
indicating that high levels of GCs present during MPTP
intoxication protect dopamine neurons. Immuno-labeling of GR
revealed its localization mainly in the nucleus of microglia and its
quantification was carried out in substantia nigra and striatum
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FIGURE 1 | Transcriptional regulation of inflammation by GR in
microglia. (A) In resting, healthy state without any cellular injury or
pathogen invasion, GR is inactive in most microglia. Toxins e.g., MPTP or
powerful inflammogen LPS would rapidly trigger innate immune response in
microglia. In the case of LPS, TLR4 present in microglia results in activation
of major transcription factors NF-κB, IRF and AP-1, known to orchestrate
an inflammatory response. Cellular injury or pro-inflammatory cytokines
would activate HPA axis and increased GC secretion. High circulating GC
levels results in GR activation in microglia, which act to repress the
transcriptional activity of NF-κB, IRF and AP-1 and also stimulating the
expression of genes such as IκB-α and or MKP-1 known to inhibit NF-κB
and AP-1 respectively. Neuronal injury and death are prevented. (B) In the
absence of GR activity in microglia, microglia remain in activated state
causing neuronal death.
in saline and MPTP injected mice. The results showed that
number of microglia with nuclear GR augmented from 35% in
resting state to 70--80% 3 days after MPTP injections, which then
declined to almost normal levels after 3 weeks. Measurement
of endogenous corticosterone levels showed a three-fold rise
1 day after MPTP (Ros-Bernal et al., 2011). Importantly,
these results indicate that GR activation during endogenous
rise in corticosterone levels is progressive concurring loss of
dopamine neurons (Figure 1). However increasing GC levels by
corticosterone treatment results in significant neuroprotection
likely because GR activation in microglia is rapid enough to
counteract the inflammatory response mounted by activated glia.
The precise actions of GR in microglia during dopamine
neurodegeneration were studied using GRLysMCre mice
(Ros-Bernal et al., 2011). Functionally, absence of GR in
microglia/macrophages resulted in significant dopamine
neuronal loss in two paradigms of MPTP intoxication: (a)
acute toxicity (4 injections/day) which is accompanied by
intense microglial and astroglial activation of short duration;
and (b) sub-chronic treatment (1 injection for 5 days) the loss
of dopamine neurons is less, and morphologically, microglial
activation is less apparent. In microglial GR mutant mice, both
MPTP paradigms augmented microglial activation i.e., number
hypertrophied microglia, compared to controls. Additionally, in
sub-chronic paradigm, GR was found to prolong the duration of
activation. Several molecules released by degenerating dopamine
neurons can potentially trigger morphological and functional
changes in microglia i.e., its activation status or its mobility
(e.g., Matrix metalloprotease MMP-9, α-synuclein, Annese
et al., 2015), however how the primary signals emitted from
degenerating dopamine neurons trigger microglial activation is
not well elucidated. With regards to regulation of inflammation,
microglial GR was found to modulate 3 classes of inflammatory
genes: (a) increasing expression of pro-inflammatory molecules
in particular, TNF-α, iNOS, Intercellular adhesion molecule
(ICAM); (b) anti-inflammatory genes e.g., MKP-1 (as described
above for inhibiting AP1 transcriptional activity) and IL-1R2
which is a decoy receptor for IL-1 receptor1; (c) inflammatory
caspases, i.e., caspases 1 and 4 as well as TLR3, TLR4, TLR9
and MyD88. The inflammatory caspases and TLRs are core
components of innate immunity important for stimulating the
transcriptional activity of AP1, NF-κB and IRF and thereby
expression of plethora of inflammatory mediators. These
findings indicate that GR not only inhibits the molecules like
TNF-α known to execute the inflammatory reaction but also
prevent excessive expression of upstream activators that initiate
an inflammatory reaction.
Nuclear expression of p65 subunit of NF-κB, indicative of
transcriptional activity NF-κB, was observed in microglia of
SNpc in PD patients as well as in mice treated with MPTP.
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FIGURE 2 | Putative roles of glucocorticoids (GC) and
glucocorticoid receptor (GR) in progression to chronic
inflammation and dopamine neurodegeneration. In healthy state,
microglia and astroglia surrounding are quiescent. Aging as well as other
stressors such as infections or PD-related genetic and environmental
factors would put immune system on alert and possibly also stimulating
HPA axis. Activation of HPA axis results in increase in GC levels and
activation of GR. In pre-clinical stage, secretion of DAMPS, such as
pathological form of α-synuclein would activate immune system as well as
HPA axis. Persistent activation of HPA axis results in loss of its regulation
and chronically high GC levels. Chronic GCs are known to result in GR
dysfunction in immune cells. Microglia and astroglia remain activated
creating a pro-inflammatory environment and augmenting oxidative stress.
Disruption in blood brain barrier resulting in T cell infiltration further
promotes glial activation. Dopamine degeneration is progressively
increased leading to clinical manifestation of PD.
Moreover inhibiting NF-κB in mice significantly protected
dopamine neurons against MPTP toxicity (Ghosh et al.,
2007). Thus sustained transcriptional activity of NF-κB is
likely involved in chronic activation of microglia in PD.
Interestingly, GR was found to associate with p65 subunit of
NF-κB in microglial cultures, as well in luciferase reporter
assays GR inhibited its transcriptional activity (Ros-Bernal
et al., 2011; Carrillo-de Sauvage et al., 2013). In vivo, Serine
276 phosphorylation of P65 subunit of NF-κB, indicative of
its activation, was sustained in MPTP-lesioned SNpc and
striatum of mutant GR microglial mice (Ros-Bernal et al.,
2011).
The halting of inflammation is central to immune response. A
failure to limit the amplitude and duration of this process as well
as initiate a resolution phase can lead to chronic inflammatory
state. In addition to GR, other members of nuclear receptor
family e.g., Peroxisome proliferator activated receptor gamma
(PPAR-γ), Liver X receptor (LXR), Estrogen receptor ER-β,
Nuclear receptor NR4A family (Nurr 77, Nurr1) are expressed in
microglia, thus they can also control microglial activation. In this
regard, Nurr1 inhibition was found to increase NF-κB activity
in glia resulting in exaggerated expression of pro-inflammatory
mediators and increased loss of dopamine neurons following LPS
injection in substantia nigra (Saijo et al., 2009).
Regarding GCs, it is possible that in PD, GR functions in
immune cells are compromised because of chronically elevated
levels of cortisol. The putative scenario of dysfunction of GR
signaling in PD is illustrated in Figure 2. Different stressors such
as aging, infections, environmental and genetic susceptibility
factors would activate HPA axis resulting in augmentation
of circulating GC levels and activation of GR. In parallel,
activation of peripheral immune system would result in increased
circulating levels of pro-inflammatory molecules e.g., Il-1β
known to activate HPA axis and also to induce microglial
priming such that any subsequent insult exacerbates microglial
inflammatory phenotype. Persistent activation of HPA axis with
chronically high cortisol levels would compromise GR functions
(Dejager et al., 2014). Further studies are needed to understand
how GR activity is affected in microglia during chronically
active HPA axis, as is the case for PD patients and whether GR
inflammatory function is affected in PD. In addition, it would
be important to understand the redundant and non-redundant
functions of GR with closely related nuclear receptor members
such as Nurr1 for envisaging therapeutic potentials in PD.
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